Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02433626
Recruitment Status : Recruiting
First Posted : May 5, 2015
Last Update Posted : February 1, 2019
Sponsor:
Collaborators:
M.D. Anderson Cancer Center
Northwestern Memorial Hospital
Information provided by (Responsible Party):
Critical Outcome Technologies Inc.

Brief Summary:

Activity of COTI-2 has been demonstrated in various cancer tumor models. With its p53- and AKT-based mechanisms of action, COTI-2 is anticipated to be highly relevant in treatment of patients with gynecologic malignancies or head and neck squamous cell carcinoma (HNSCC) as well as a variety of other tumor types.

This study is designed primarily to assess the safety and tolerability of COTI-2 monotherapy or combination therapy in patients with advanced and recurrent malignancies to establish a recommended Phase 2 dose (RP2D) for future studies.

Patients are currently being recruited for Part 3 of the study.

Critical Outcome Technologies Inc. has been renamed to Cotinga Pharmaceuticals.


Condition or disease Intervention/treatment Phase
Ovarian Cancer Fallopian Tube Cancer Endometrial Cancer Cervical Cancer Peritoneal Cancer Head and Neck Cancer HNSCC Colorectal Cancer Lung Cancer Pancreatic Cancer Drug: COTI2 Drug: Cisplatin Phase 1

Detailed Description:

This is a three-part, multi-center, open-label, Phase 1, first-in-patient study of COTI-2 in patients with recurrent ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancer (collectively gynecological malignancies), and in patients with head and neck squamous cell carcinoma (HNSCC), colorectal, lung, or pancreatic cancer. Other tumor types may be allowed with Sponsor approval.

COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week.

Part 1 of the study will be dose finding in patients with gynecological malignancies using a 3 + 3 design to establish the MTD (maximum tolerated dose) over 6 planned cohorts.

Part 2 of the study will be dose finding in patients with HNSCC using a 3 + 3 design to establish the MTD over 6 planned cohorts.

Part 3 of the study will be dose finding for COTI-2 in combination with cisplatin in patients with gynecological malignancies, HNSCC, colorectal, lung, pancreatic cancer, or other tumor types with Sponsor approval.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 51 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies
Study Start Date : December 2015
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : June 2020


Arm Intervention/treatment
Experimental: COTI2
COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 4 weeks of treatment as described (5 days on, 2 days off per week). Participants will remain on treatment until they experience a lack of benefit.
Drug: COTI2
COTI-2 is a third generation thiosemicarbazone.
Other Name: CAS 1039455-84-9; 4-(2-pyridinyl)-2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide-1-piperazinecarbothioic acid

Experimental: COTI2 + cisplatin
COTI-2 will be self-administered as a single agent, orally, once daily for 5 days followed by 2 treatment-free days each week; 1 cycle will be defined as 3 weeks of treatment as described (5 days on, 2 days off per week). Cisplatin 60 mg/m2 IV will be administered on Day 1 of each 3 week cycle. Participants will remain on treatment until they experience a lack of benefit.
Drug: COTI2
COTI-2 is a third generation thiosemicarbazone.
Other Name: CAS 1039455-84-9; 4-(2-pyridinyl)-2-(6,7-dihydro-8(5H)-quinolinylidene)hydrazide-1-piperazinecarbothioic acid

Drug: Cisplatin
Cisplatin is approved to treat a range of solid tumors and lymphomas.
Other Name: CAS 15663-27-1; CDDP




Primary Outcome Measures :
  1. Number of dose limiting Toxicities [ Time Frame: 12 months ]
    Used to measure safety and tolerability of COTI2

  2. Tmax [ Time Frame: 6 months ]
    To determine maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D)


Secondary Outcome Measures :
  1. Clinical response [ Time Frame: 6 Months ]
    This will be assessed through CT imaging, measurement using RECIST 1.0 criteria and GCIG criteria (if applicable)

  2. Progression Free survival [ Time Frame: 12 months ]
    This will be assessed through CT imaging and measurement using RECIST 1.0 criteria.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  1. ≥18 years of age.
  2. Willing and able to provide written informed consent to participate in this investigational study.
  3. Cancer that is recurrent, metastatic, or unresectable and for which no effective or curative measures exist.

    • Part 1: Ovarian, fallopian tube, primary peritoneal, endometrial, or cervical cancer
    • Part 2: HNSCC, with confirmed p53 mutations
    • Part 3: Gynecological malignancies, HNSCC, colorectal, lung, pancreatic cancer, or other tumors with Sponsor approval.
  4. Ability to attend all scheduled study visits
  5. Measurable disease by physical examination or imaging as defined by RECIST v1.1 criteria or evaluable disease as defined by Gynecologic Cancer Intergroup (GCIG) CA125 criteria.
  6. European Cooperative Oncology Group (ECOG) performance status 0 or 1.
  7. Life expectancy ≥3 months.
  8. Adequate bone marrow, liver, renal, and cardiac function at study entry, assessed as follows:

    • Hemoglobin ≥9.0 g/dL;
    • Absolute neutrophil count (ANC) ≥1.5 x 109/L;
    • Platelet count ≥100 x 109/L;
    • Prothrombin time (PT) or international normalize rate (INR) within 1.5x upper limit of normal;
    • Partial thromboplastin time (PTT) within 1.5x upper limit of normal;
    • Total bilirubin within normal limits;
    • Alanine transaminase (ALT) and aspartate transaminase (AST) within 1.5x upper limit of normal;
    • Calculated creatinine clearance >50 mL/min;
    • Urine protein <500 mg or urine protein: creatinine ratio (UPC) <1.0; and
    • Left ventricular ejection fraction (LVEF) ≥55% (or the institutional lower limit of normal [LLN]) as evidenced on ECHO.
  9. Prior chemotherapy, other investigational agents, or radiation must be discontinued for at least 28 days prior to the first administration of COTI-2. Hormone treatments must be discontinued for at least 28 days prior to the first administration of COTI-2.
  10. Toxicity from prior therapy (except alopecia) has resolved to ≤Grade 1; in the event of toxicity that has not resolved to ≤Grade 1 but is considered stable, the patient may be eligible after discussion among the investigator and sponsor's medical monitor.
  11. Physiologically incapable of becoming pregnant, postmenopausal, or negative pregnancy test and agree to use adequate contraception (e.g., oral contraceptive, double barrier method, intra-uterine device, intra-muscular contraceptive).
  12. Patients enrolled in the expansion phase must be willing to undergo pre and post-Cycle 1 biopsies.
  13. Patients enrolled in the escalation and expansion phases will be required to have archival tissue available for analysis.

Exclusion Criteria:

  1. Pregnant or lactating.
  2. History of other invasive malignancies, with the exception of non-melanoma skin cancer or successfully treated in situ carcinoma, if there is evidence of the malignancy being present within the last 3 years.
  3. Inability to tolerate oral medications.
  4. Any serious and/or unstable pre-existing medical, psychiatric, or other condition (e.g., severe hepatic impairment) or current unstable or uncompensated respiratory or cardiac conditions which makes it undesirable for the patient to participate in the study or which could jeopardize compliance with the protocol.
  5. History of clinically significant or uncontrolled cardiac disease including but not limited to:

    1. Myocardial infarction,
    2. Angina pectoris,
    3. Congestive heart failure of New York Heart Association (NYHA) Grade >2,
    4. Ventricular arrhythmias requiring continuous therapy, or
    5. Supraventricular arrhythmias including atrial fibrillation, which are uncontrolled.
  6. Major surgery, excluding skin biopsies and procedures for insertion of central venous access devices, within 28 days prior to the start of COTI-2.
  7. Active, uncontrolled bacterial, viral, fungal, or other opportunistic infection requiring systemic therapy.
  8. Part 2:

    1. The presence of or imminent occurrence of airway obstruction, unless tracheostomy in place.
    2. HPV-positive status ( In HNSCC patients only)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02433626


Contacts
Layout table for location contacts
Contact: Richard Ho, MD-PhD rho@cotingapharma.com

Locations
Layout table for location information
United States, Texas
MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Contact: Shannon Westin, MD    713-794-4314      
Principal Investigator: Shannon Westin, MD         
Sponsors and Collaborators
Critical Outcome Technologies Inc.
M.D. Anderson Cancer Center
Northwestern Memorial Hospital
Investigators
Layout table for investigator information
Principal Investigator: Shannon Westin, MD MD Anderson

Publications:
Kalsi JK, Manchanda R, Menon U. Screening for gynecological cancers. Expert Rev Obstet Gynecol 2013;8(2):143-60.
Leary A, Auclin E, Pautier P, Lhommé C. The PI3K/Akt/mTOR pathway in ovarian cancer: biological rationale and therapeutic opportunities. In: Ovarian cancer - a clinical and translational update. InTech; 2013, pp. 275-302.

Layout table for additonal information
Responsible Party: Critical Outcome Technologies Inc.
ClinicalTrials.gov Identifier: NCT02433626     History of Changes
Other Study ID Numbers: COTI2-101
First Posted: May 5, 2015    Key Record Dates
Last Update Posted: February 1, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Pancreatic Neoplasms
Head and Neck Neoplasms
Uterine Cervical Neoplasms
Endometrial Neoplasms
Fallopian Tube Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Endocrine Gland Neoplasms
Pancreatic Diseases
Endocrine System Diseases
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female
Fallopian Tube Diseases
Adnexal Diseases
Cisplatin
Antineoplastic Agents